 |
|
High-tech spectroscopy may be used to monitor neuropsychiatric symptoms
November 13, 2006WINSTON-SALEM, N.C. - Magnetic resonance spectroscopy (MRS) may provide a noninvasive way to monitor neuropsychiatric symptoms in patients with lupus, according to results from research in mice at Wake Forest University School of Medicine.
"This study is the first to demonstrate that MRS is a feasible method to monitor neuropsychiatric symptoms in lupus," said Nilamadhab Mishra, M.D., the principal investigator, in a presentation at the American College of Rheumatology meeting in Washington.
MRS is closely related to MRI (magnetic resonance imaging), and uses strong magnetic fields and low energy radio waves to get biochemical information about the body. The test is done in an MRI machine to which a spectrometer has been attached to measure changes in metabolites, such as the levels of glutamate and glutamine.
"Because of its noninvasiveness and repeatable nature, MRS could be helpful in the drug discovery program for neuropsychiatric lupus," said Mishra, an assistant professor of rheumatology. He explained, "No definitive biomarker of neuropsychiatric lupus is available and this impedes both clinical diagnosis and drug discovery for treatment of this condition."
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), in neuropsychiatric lupus, there are a wide variety of associated neurological and psychiatric syndromes and cognitive problems.
NIAMS, which is supporting Mishra's work, said that about 20 percent of lupus patients have neuropsychiatric symptoms and it is one of the major causes of death among people with lupus. Systemic lupus affects an estimated 1.5 million Americans, mostly women.
In his study, Mishra is using mice that have a defective gene and spontaneously develop lupus, including lymph node swelling and increased spleen size. He is comparing these animals with control animals that do not have lupus.
His results showed "a dramatic decrease" in the ratio of two biochemicals, glutamate and glutamine as measured by MRS in the mice with lupus compared with control mice as early as seven weeks of life, which directly paralleled behavioral tests. Other biochemical pairs also showed changes, but not as dramatically as glutamate/glutamine. At 11 and 15 weeks, there were significant further decreases in the glutamate/glutamine ratio.
Mishra and his colleagues tested cognitive performance using a water maze test, a standard test to assess spatial learning and memory in rodents. "The water maze test measures memory, learning and cognitive function. We correlated the changes in metabolites in different age groups to behavior changes," he said.
The mice in the lupus group had significantly poorer cognitive function at seven weeks, tracking the decline in the glutamate/glutamine ratio. Cognitive function "continued to deteriorate further with advancing age, whereas there was no change in control mice."
"This tells us that MRS can be useful for monitoring the disease instead of time-consuming behavioral studies," he said. The changes in the glutamate/glutamine ratio indicate that the neuropsychiatric lupus is getting progressively worse.
But precisely how the biochemical changes equate to neuropsychiatric symptoms in people will await future human studies, he said.
Wake Forest University Baptist Medical Center
"Because of its noninvasiveness and repeatable nature, MRS could be helpful in the drug discovery program for neuropsychiatric lupus," said Mishra, an assistant professor of rheumatology. He explained, "No definitive biomarker of neuropsychiatric lupus is available and this impedes both clinical diagnosis and drug discovery for treatment of this condition."
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), in neuropsychiatric lupus, there are a wide variety of associated neurological and psychiatric syndromes and cognitive problems.
NIAMS, which is supporting Mishra's work, said that about 20 percent of lupus patients have neuropsychiatric symptoms and it is one of the major causes of death among people with lupus. Systemic lupus affects an estimated 1.5 million Americans, mostly women.
In his study, Mishra is using mice that have a defective gene and spontaneously develop lupus, including lymph node swelling and increased spleen size. He is comparing these animals with control animals that do not have lupus.
His results showed "a dramatic decrease" in the ratio of two biochemicals, glutamate and glutamine as measured by MRS in the mice with lupus compared with control mice as early as seven weeks of life, which directly paralleled behavioral tests. Other biochemical pairs also showed changes, but not as dramatically as glutamate/glutamine. At 11 and 15 weeks, there were significant further decreases in the glutamate/glutamine ratio.
Mishra and his colleagues tested cognitive performance using a water maze test, a standard test to assess spatial learning and memory in rodents. "The water maze test measures memory, learning and cognitive function. We correlated the changes in metabolites in different age groups to behavior changes," he said.
The mice in the lupus group had significantly poorer cognitive function at seven weeks, tracking the decline in the glutamate/glutamine ratio. Cognitive function "continued to deteriorate further with advancing age, whereas there was no change in control mice."
"This tells us that MRS can be useful for monitoring the disease instead of time-consuming behavioral studies," he said. The changes in the glutamate/glutamine ratio indicate that the neuropsychiatric lupus is getting progressively worse.
But precisely how the biochemical changes equate to neuropsychiatric symptoms in people will await future human studies, he said.
Wake Forest University Baptist Medical Center
Neuropsychiatric News and Current Neuropsychiatric Events RSSResearchers link cocoa flavanols to improved brain blood flow
Cocoa flavanols, the unique compounds found naturally in cocoa, may increase blood flow to the brain, according to new research published in the Neuropsychiatric Disease and Treatment journal. The researchers suggest that long-term improvements in brain blood flow could impact cognitive behavior, offering future potential for debilitating brain conditions including dementia and stroke.
'Erasing' drug-associated memories may stop drug addiction relapses
'Erasing' drug-associated memories may prevent recovering drug abusers from relapsing, researchers at the University of Cambridge have discovered.
Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.
Alcoholism-associated molecular adaptations in brain neurocognitive circuits
After many years of heavy drinking, alcohol produces pathological alterations in the brain. In many alcoholics these changes culminate in massive social deterioration and disorders of memory and learning.
Scientists Find Stem Cells For the First Time in the Pituitary
A team of researchers led by scientists at Cold Spring Harbor Laboratory have for the first time identified stem cells that allow the pituitary glands of mice to grow even after birth.
Survey offers first-ever look at treatment practices for nonepileptic seizures
A new nationwide clinician survey provides the first comprehensive look at what is community care or 'treatment as usual' for nonepileptic seizures (NES), laying the groundwork for clinical trials aimed at identifying effective treatments for this neuropsychiatric disorder.
First look: Princeton researchers peek into deepest recesses of human brain
A team of scientists from Princeton University has devised a new experimental technique that produces some of the best functional images ever taken of the human brainstem, the most primitive area of the brain.
New treatment mechanisms for schizophrenia
The field of schizophrenia research has come alive with many exciting new potential approaches to treatment. From the introduction of chlorpromazine to the current day, all treatments approved by the U.S. Food and Drug Administration have had, at their core, a single treatment mechanism, the blockade of the dopamine D2 receptor.
Some antipsychotic drugs may be missing their mark
Drugs that treat depression, schizophrenia and other psychotic conditions and that target a particular protein on brain cells might not be triggering the most appropriate response in those cells, new research suggests.
New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
The 2007 American College of Neuropsychopharmacology Annual Meeting will feature hundreds of new studies on brain and behavior from the world's leading scientists. Presentations include innovative research on potential new treatments for depression, post-traumatic stress disorder, autism and addiction.
More Neuropsychiatric News Articles
 | Anatomy of Neuropsychiatry: The New Anatomy of the Basal Forebrain and its Implications for Neuropsychiatric Illness by Lennart Heimer, Gary W. Van Hoesen, Michael Trimble, Daniel S. Zahm This book presents the anatomical systems that take part in the scientific and clinical study of emotional functions and neuropsychiatric disorders. It discusses the limbic systemthe cortical and subcortical structures in the human brain involved in emotion, motivation, and emotional association with memoryat length and how this is no longer a useful guide to the study of psychiatric disorders.... |
 | "It's All In Your Head," Patient Stories From the Front Lines (Large Print): Intimate Aspects of Chronic and Neuropsychiatric Lyme Disease by PJ Langhoff The History of Lyme disease, tick-borne illnesses, testing, and the politics and personal stories as told by Lyme... |
 | Neuropsychological Assessment of Neuropsychiatric Disorders A 1996 survey of the members of the American Board of Professional Psychology Diplomates, published by The Clinical Neuropsychologist journal, selected the first edition of this book as one of the "Essential Books and Journals in North American Clinical Neuropsychology"--a list which included only 10 other titles! The Second Edition has improved further on this high standard. While the authors... |
 | Traumatic Brain Injury: Methods for Clinical & Forensic Neuropsychiatric Assessment, Second Edition by Jr., Robert P. Granacher A comprehensive introduction to evaluating and treating patients with traumatic brain injuries, this second edition of a bestseller features new information regarding the epidemiology and pathophysiology of brain injury as well as structural and functional imaging in the assessment of traumatic brain injury, including functional MRI, PET scanning, and magnetic resonance spectroscopy. With... |
 | Homocysteine. Related Vitamins and Neuropsychiatric Disorders by Christina Bolander-Gouaille, Téodoro Bottiglieri During the last 15 years the research on homocysteine and the vitamins involved in its metabolism has become very dynamic. About 1,500 publications on the subject are now published each year. The research has long mainly focused on the association between homocysteine and cardiovascular disease, but also pregnancy complications/ fetal malformations. There is, however, an increasing interest in... |
 | Optimal Treatment for Children with Autism and other Neuropsychiatric Conditions by Dr. Jean-Ronel Corbier 1 out of every 6 children in America suffers from problems such as autism, ADHD, dyslexia and aggression! Why? Is your child at risk? Dr. Jean-Ronel Corbier provides a comprehensive and unique look at autism and other neuropsychiatric conditions providing vital information to parents, professionals and others concerned with neurodevelopmental disorders. Optimal Treatment for Children with... |
 | Traumatic Brain Injury: Methods for Clinical and Forensic Neuropsychiatric Assessment by Jr., Robert P. Granacher Numerous books exist on traumatic brain injury, yet none comprehensively cover evaluation from both clinical and forensic standpoints. Traumatic Brain Injury: Methods for Clinical and Forensic Neuropsychiatric Assessment is the first medical book to guide treatment practitioners not only in methods for evaluating traumatic brain injury in adults and children, but also in the important elements of... |
| Neuropsychiatric Mental Status Examination by Michael Alan Taylor | |
 | Insulin Resistance Syndrome and Neuropsychiatric Disease (Medical Psychiatry) The first book of its kind to tie the metabolic syndrome with psychiatric disorders, and the possibility that common antipsychotic treatments may be having an adverse effect on patients. Insulin Resistance Syndrome and Neuropsychiatric Disorders describes: · he impact on treatment · psychiatric and cognitive disorders · insulin resistance · the relationship that... |
| Neuropsychiatric Mental Status Examination by Michael A. Taylor |
| © 2008 BrightSurf.com |